Generics - Johnson & Johnson


Current filters:

Johnson & Johnson

Popular Filters

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan


Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

Mallinckrodt questions FDA reasoning on methylphenidate ER reclassification


US drugmaker Mallinckrodt says it has been informed by the Food and Drug Administration that the agency…

ConcertaGenericsJohnson & JohnsonMallinckrodtMethylphenidate Extended-Release TabletsNeurologicalRegulationUSA

J&J’s Janssen units file Citizen Petition with FDA on biosimilars naming

J&J’s Janssen units file Citizen Petition with FDA on biosimilars naming


Health care giant Johnson & Johnson’s Janssen Pharmaceutical companies have submitted a Citizen Petition…

BiosimilarsGenericsJanssenJohnson & JohnsonNorth AmericaRegulationUSA

UK lags behind some European countries in biosimilars uptake, new study finds


New research has shown that the UK lags behind some European countries in terms of biosimilars uptake,…

CellTrionepoetinEuropeFilgrastimGenericsHealthcareinfliximabJohnson & JohnsonRemsima

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J


Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

FDA approval of generic cancer drug Doxil is expected to help resolve shortage


The US Food and Drug Administration has approved the first generic version of the cancer drug Doxil (doxorubicin…

DoxilGenericsJohnson & JohnsonLipodoxNorth AmericaOncologyRegulationSun Pharmaceutical Industries

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis


The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

European Commission enforcement action in pharmaceutical sector following sector inquiry


Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Impax Labs and Teva settle Concerta litigation with J&J units


USA-based Impax Laboratories (Nasdaq: IPXL) and the US unit of Israel generics giant Teva Pharmaceutical…

ALZA CorpConcertaGenericsImpax LaboratoriesJanssenJohnson & JohnsonNeurologicalNorth AmericaPatentsTeva Pharmaceutical Industries

Senior appointments at Teva and Johnson & Johnson


Israel's Teva Pharmaceutical Industries (NYSE: TEVA) has announced the appointment of Itzhak Krinsky…

GenericsJohnson & JohnsonManagementPharmaceuticalTeva Pharmaceutical Industries

World's first (official) biosimilar antibody goes to reumatoid arthritis


The end of July 2012 proved exciting for the world of biosimilar manufacturers. However, for the regulatory…

BiotechnologyCellTrionGenericsGlobalinfliximabJohnson & JohnsonMarkets & MarketingRegulationRemicadeRemsima



Back to top